Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $11.05, for a total value of $22,100.00. Following the completion of the sale, the president now directly owns 2,940,467 shares of the company’s stock, valued at approximately $32,492,160.35. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Gyre Therapeutics Stock Performance

Shares of NASDAQ GYRE opened at $10.66 on Friday. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $30.40. The firm has a fifty day simple moving average of $12.90 and a two-hundred day simple moving average of $12.58.

Hedge Funds Weigh In On Gyre Therapeutics

Large investors have recently modified their holdings of the stock. FMR LLC bought a new stake in shares of Gyre Therapeutics in the third quarter worth $47,000. Barclays PLC increased its holdings in Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares during the last quarter. Rhumbline Advisers bought a new position in shares of Gyre Therapeutics during the 2nd quarter valued at approximately $123,000. Renaissance Technologies LLC bought a new position in shares of Gyre Therapeutics in the 2nd quarter valued at about $166,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Gyre Therapeutics during the 2nd quarter valued at approximately $218,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.